UPGL00004
- CAS No.
- 1890169-95-5
- Chemical Name:
- UPGL00004
- Synonyms
- UPGL00004;UPGL00004,UPGL-00004;UPGL00004, 10 mM in DMSO;2-Phenyl-N-(5-(4-((5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl)amino)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide;Benzeneacetamide, N-[5-[4-[[5-[(2-phenylacetyl)amino]-1,3,4-thiadiazol-2-yl]amino]-1-piperidinyl]-1,3,4-thiadiazol-2-yl]-;2-Phenyl-N-(5-(4-((5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl)amino)piperidin-1-yl)-1,3,4-thiadiazol-2-yl)acetamide , UPGL00004
- CBNumber:
- CB04800860
- Molecular Formula:
- C25H26N8O2S2
- Molecular Weight:
- 534.66
- MDL Number:
- MOL File:
- 1890169-95-5.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Density | 1.460±0.06 g/cm3(Predicted) |
|---|---|
| storage temp. | 2-8°C |
| solubility | DMSO: 2mg/mL, clear |
| form | Solid |
| pka | 9.23±0.50(Predicted) |
| color | Off-white to gray |
| InChIKey | MRYCNTHLPRENBA-UHFFFAOYSA-N |
| SMILES | O=C(CC1=CC=CC=C1)NC(S2)=NN=C2N(CC3)CCC3NC4=NN=C(NC(CC5=CC=CC=C5)=O)S4 |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
UPGL00004 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Cayman Chemical | 42323 | UPGL00004 ≥95% | 1890169-95-5 | 5mg | $87 | 2026-04-30 | Buy |
| Cayman Chemical | 42323 | UPGL00004 ≥95% | 1890169-95-5 | 10mg | $139 | 2026-04-30 | Buy |
| Cayman Chemical | 42323 | UPGL00004 ≥95% | 1890169-95-5 | 25mg | $283 | 2026-04-30 | Buy |
| Cayman Chemical | 42323 | UPGL00004 ≥95% | 1890169-95-5 | 50mg | $479 | 2026-04-30 | Buy |
| Biosynth | QAD16995 | UPGL00004 | 1890169-95-5 | 10mg | $551.7 | 2026-06-04 | Buy |
UPGL00004 Chemical Properties,Uses,Production
Uses
UPGL00004 is a potent allosteric glutaminase C (GAC) inhibitor (IC50=29 nM; Kd=27 nM). UPGL00004 strongly inhibits the proliferation of highly aggressive triple-negative breast cancer cell lines[1].
Biological Activity
UPGL00004 is a potent glutaminase C (GAC) inhibitor with IC50 of 29 nM, more selective for GAC than GLS2.
in vitro
Administration of UPGL00004 in combination with the anti-VEGF antibody bevacizumab effectively inhibited triple-negative breast cancer cell growth and tumor growth.
in vivo
Administration of UPGL00004 in combination with the anti-VEGF antibody bevacizumab inhibited tumor growth in a human xenograft model of breast cancer.
target
| Target | Value |
| glutaminase C (Cell-free assay) | < td style="border-bottom: 1px dotted #ccc;padding: 5px;"> 29 nM
References
[1] Huang Q, et al. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism. J Biol Chem. 2018 Mar 9;293(10):3535-3545. DOI:10.1074/jbc.M117.810101
UPGL00004 Preparation Products And Raw materials
Raw materials
Preparation Products
UPGL00004 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Lollane Biological Technology Co.,Ltd. | 021-52996696，15000506266 15000506266 | China | 4861 | 55 | |
| BOC Sciences | 16314854226 | info@bocsci.com | United States | 9909 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Shanghai Rechem science Co., Ltd. | 021-31433387 15618786686 | sales@rechemscience.com | China | 2971 | 58 |
| Shanghai Chaolan Chemical Technology Center | QQ：65489617 13301690235 | Sales@ATKchemical.com | China | 9699 | 58 |
| MQ (shanghai) Pharmaceuticals Co., Ltd. | 13761635123 | sales@linyuepharm.com | China | 5731 | 55 |
| Shenzhen SUNGENING Bio-Medical Co., Ltd. | 0755-28967200 13631290199 | wxf@sungening.com | China | 9609 | 60 |
| Heze Development Zone chuangli Chemical Co., Ltd. | 0530-+86-530-529 6766，+86-15666160102 15666160102 | info@chuangli-chem.com | China | 849 | 55 |
| Shanghai Yu Ben Biotechnology Co., Ltd. | 021-61350663 15502154572 | 1639466865@qq.com | China | 499 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
